Barclays’s IGC Pharma IGC Stock Holding History

Barclays’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$196	Buy	+721	New	+$213	﹤0.01%	5113
2021 Q2	–	Sell	-537	Closed	-$1K	–	4957
2021 Q1	$1K	Buy	+537	New	+$976	﹤0.01%	4593
2020 Q3	–	Sell	-6,386	Closed	-$4K	–	5368
2020 Q2	$4K	Buy	+6,386	New	+$3.46K	﹤0.01%	5401
2019 Q3	–	Sell	-100	Closed	–	–	6891
2019 Q2	$0	Buy	+100	New	+$141	﹤0.01%	7072

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Barclays's IGC Position: Q2 2026 in Review

Barclays opened a new position in IGC Pharma (IGC) in Q2 2026: 721 shares worth $196. The stake represents ﹤0.01% of the portfolio and ranks #5113 among its holdings. This is a return to the name: Barclays previously reported a position in IGC as recently as Q1 2021.

Barclays first reported a position in IGC in Q2 2019 and has held it in 4 quarters since. The position peaked at $4K in Q2 2020. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

Barclays held 721 shares of IGC Pharma worth $196 as of Q2 2026.
IGC Pharma was a new Barclays position in Q2 2026.
IGC Pharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5113 holding.
Barclays first reported a position in IGC Pharma in Q2 2019 and has held it in 4 quarters since.
Barclays's IGC Pharma position peaked at $4K in Q2 2020.
36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.